Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7172 + AG
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
HRS-7172 + AG is an investigational combination regimen consisting of HRS-7172, a novel small molecule pan-RAS(on) molecular glue, combined with the AG chemotherapy regimen (albumin-bound paclitaxel [nab-paclitaxel] and gemcitabine). Developed by Jiangsu Hengrui Pharmaceuticals, HRS-7172 is designed to target tumors harboring RAS mutations or amplifications by binding to Cyclophilin A (PPIA) and active GTP-bound RAS proteins to form a stable tri-complex, thereby blocking downstream oncogenic signaling. The combination is being evaluated in a Phase IB/II clinical trial for the treatment of advanced or metastatic pancreatic cancer and other solid tumors with RAS mutations or amplifications.
- Other names
- HRS-7172 + AGHRS-7172 + gemcitabine + nab-paclitaxelHRS-7172 + gemcitabine + paclitaxelHRS-7172 in combination with AGHRS7172 in combination with AGHRS 7172 in combination with AGHRS-7172 in combination with gemcitabine and nab-paclitaxelHRS7172 in combination with gemcitabine and nab-paclitaxelHRS 7172 in combination with gemcitabine and nab-paclitaxelHRS-7172 in combination with gemcitabine and paclitaxelHRS7172 in combination with gemcitabine and paclitaxelHRS 7172 in combination with gemcitabine and paclitaxelHRS-7172 in combination with nab-paclitaxel and gemcitabineHRS7172 in combination with nab-paclitaxel and gemcitabineHRS 7172 in combination with nab-paclitaxel and gemcitabineHRS-7172 in combination with paclitaxel and gemcitabineHRS7172 in combination with paclitaxel and gemcitabineHRS 7172 in combination with paclitaxel and gemcitabineHRS-7172 plus AGHRS7172 plus AGHRS 7172 plus AGHRS-7172 plus gemcitabine and nab-paclitaxelHRS7172 plus gemcitabine and nab-paclitaxelHRS 7172 plus gemcitabine and nab-paclitaxelHRS-7172 plus gemcitabine and paclitaxelHRS7172 plus gemcitabine and paclitaxelHRS 7172 plus gemcitabine and paclitaxelHRS-7172 plus nab-paclitaxel and gemcitabineHRS7172 plus nab-paclitaxel and gemcitabineHRS 7172 plus nab-paclitaxel and gemcitabineHRS-7172 plus paclitaxel and gemcitabineHRS7172 plus paclitaxel and gemcitabineHRS 7172 plus paclitaxel and gemcitabine
02
Targets
HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)RRM1DNAPPIA (Peptidyl-prolyl cis-trans isomerase A)TUBB (Tubulin (alpha and beta subunits))NRAS (Neuroblastoma RAS viral oncogene homolog)
Beyond the preview
Go deeper on HRS-7172 + AG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7172 + AG.